期刊
ONCOIMMUNOLOGY
卷 6, 期 10, 页码 -出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/2162402X.2017.1290036
关键词
Cancer immunotherapy; clinical trials; cancer vaccines; liposomes; nanoparticles
资金
- National Institutes of Health [R01CA175517, R01CA195563]
Conventional cancer treatments remain insufficient to treat many therapy-resistant tumors.(1) Cancer vaccines attempt to overcome this resistance by activating the patient's immune system to eliminate tumor cells without the toxicity of systemic chemotherapy and radiation. Nanoparticles (NPs) are promising as customizable, immunostimulatory carriers to protect and deliver antigen. Although many NP vaccines have been investigated in preclinical settings, a few have advanced into clinical application, and still fewer have demonstrated clinical benefit. This review incorporates observations from NP vaccines that have been evaluated in early phase clinical trials to make recommendations for the next generation of NP-based cancer vaccines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据